International Stem Cell Corporation Granted Key US Patent Protecting Anti-Aging Business
CARLSBAD, CA. -- January 15, 2019 -- Investorshub NewsWire -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based, clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company US Patent No. 10,172,890 on the topical use of lysate from human parthenogenetic (non-embryonic) stem cells to visibly improve signs of skin aging. The patented stem cell lysate is encapsulated and delivered from protective liposomes, and is combined with antioxidants, vitamins and peptides to provide skin benefits including reducing the depth/number of facial fine lines and wrinkles, increasing skin elasticity/firmness, and improving skin hydration. This proven to be effective technology used in the products was developed by key ISCO scientists, who brought neural stem cells to the clinical trial for the treatment of Parkinson’s disease.
“It is important that ISCO’s intellectual property portfolio continues to expand and we are excited to receive this US patent covering a technology used in Lifeline’s stem cell-based product line, which won various prestigious awards and has been receiving positive feedback both from consumers and well-known doctors since 2010 when we launched the product line” – commented Russell Kern, PhD, Co-Founder and CEO of Lifeline Skin Care, Inc.
ISCO’s wholly-owned subsidiary Lifeline Skin Care®, Inc. is a cosmeceutical business which develops, manufactures and markets anti-aging topical products using a proprietary extract derived from human parthenogenetic (non-embryonic) stem cells (hpSC) that has been shown to have a beneficial effect on skin cells. Currently Lifeline has developed and markets nineteen products. The products have been clinically tested by third party to ensure safety and efficacy.
Lifeline Skin Care’s products are sold nationally and internationally through a branded website www.lifelineskincare.com, various e-tailers such as Amazon, as well as through dermatology and cosmetic surgery offices, medical, day and resort spas. The goal of Lifeline is to help individuals improve the look and feel of their skin by combining the latest discoveries in the fields of stem cell biology, nanotechnology and skin cream formulation technology to create the highest quality, scientifically tested and most effective skin care products.
About International Stem Cell Corporation
International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
International Stem Cell Corporation
Russell A. Kern, PhD
Vice President, Investor Relations